Under a five-year agreement with the drug and medical device industry, the FDA will receives approximately $6.4 billion in user fees to fund reviews of drugs and medical devices.
Those fees, however, cannot be used until the FDA receives federal funding, which is at stake as $1.2 trillion of federal budget cuts set in through 2012. Under the Budget Control Act, the FDA could lose as much as $200 million for fiscal year 2013. The funding could affect not only product reviews but also jobs at the federal agency.
Lawmakers are currently at a stalemate on whether to comply with the funding cuts required under the Budget Control Act.
More Articles on the FDA:
InVivo Therapeutics Names Interim Chief Science Officer
EOS, IMDS Partner for Medical Devices
